Is Traws Pharma, Inc. overvalued or undervalued?

As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued based on its current metrics, particularly with a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%.
When compared to peers, Traws Pharma's P/E ratio of 0.2145 stands in stark contrast to Catalyst Biosciences, Inc., which is considered expensive at a P/E of 110.0436, and Elutia, Inc., which has a risky valuation with a P/E of -2.8330. This suggests that Traws Pharma may offer a more favorable investment opportunity relative to its peers. Although specific return data is not available, the lack of negative returns compared to the S&P 500 reinforces the notion that Traws Pharma is positioned well in the market.